Last reviewed · How we verify
NCT06604260: PIMAFI
FAPi-PET Imaging of in Vivo Fibrosis in Inflammatory Bowel Disease Patients
Phase 2 trial testing 68Ga-FAPi-46 in IBD (Inflammatory Bowel Disease) in 20 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Dalia Lartey |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 20 |
| Start date | 31 August 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- 68Ga-FAPi-46 — full drug profile →
Conditions studied
- IBD (Inflammatory Bowel Disease) — all drugs for IBD (Inflammatory Bowel Disease) →
- Crohn Disease (CD) — all drugs for Crohn Disease (CD) →
- Ulcerative Colitis (UC) — all drugs for Ulcerative Colitis (UC) →
Sponsor
Dalia Lartey
Who can join
18 and older, any sex, with IBD (Inflammatory Bowel Disease) or Crohn Disease (CD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our main objective is to evaluate the feasibility of 68Ga-FAPi PET/CT in detecting intestinal fibrosis in patients with IBD. To this end, we will determine 68Ga-FAPi uptake in IBD in relation to cellular FAP expression in intestinal biopsies and resection specimens.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials.
Palihati M, Das JP, Yeh R, Capaccione K. · · 2025 · cited 5× · PMID 40863874 · DOI 10.3390/tomography11080083
Verify or expand the search:
- PubMed search for NCT06604260
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 68Ga-FAPi-46
Trials testing the same drug.
- NCT05898854 — [68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer · Phase 2 · completed
- NCT05903807 — [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer · Phase 2 · recruiting
- NCT05263700 — FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary · NA · unknown
Other recruiting trials for IBD (Inflammatory Bowel Disease)
Currently open trials in the same condition.
- NCT07385807 — Exploring Fecal Calprotectin Levels, Maternal and Infant Microbiota, Infant Health, Nutrition, and Adverse Pregnancy Out · recruiting
- NCT07353853 — Pre-packaged Low-residue Diet for Bowel Preparation in Patients With Inflammatory Bowel Disease · NA · recruiting
- NCT07335705 — Analysis of Factors Influencing the Quality of Bowel Preparation Before Colonoscopy in IBD Patients · recruiting
- NCT07195123 — Evaluation of the SMART IBD App in Pediatric IBD · NA · recruiting
- NCT07168499 — Diet and Stress Management Combined With Advanced Therapy for Crohn's and Ulcerative Colitis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06604260 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dalia Lartey
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06604260.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing